Michael Gelband’s Galectin Therapeutics GALT Stock Holding History

Michael Gelband’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-82,478	Closed	-$343K	–	1738
2025 Q4	$343K	Buy	+82,478	New	+$434K	﹤0.01%	1274
2024 Q4	–	Sell	-29,552	Closed	-$81K	–	1696
2024 Q3	$81K	Buy	+29,552	New	+$72.6K	﹤0.01%	1521
2021 Q3	–	Sell	-42,042	Closed	-$135K	–	2298
2021 Q2	$135K	Buy	+42,042	New	+$150K	﹤0.01%	2082
2019 Q2	–	Sell	-70,854	Closed	-$362K	–	1185
2019 Q1	$362K	Buy	70,854 +36,254	+105%	+$174K	0.03%	416
2018 Q4	$119K	Buy	+34,600	New	+$165K	0.01%	302

Other funds holding GALT

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Michael Gelband's GALT Position: Q1 2026 in Review

Michael Gelband sold out of Galectin Therapeutics (GALT) in Q1 2026, closing a stake of 82,478 shares — an estimated $343K sold.

Michael Gelband first reported a position in GALT in Q4 2018 and held it in 5 quarters. The position peaked at $362K in Q1 2019. 99 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

Michael Gelband reported no remaining Galectin Therapeutics position as of Q1 2026 after selling out during the quarter.
Michael Gelband sold 82,478 Galectin Therapeutics shares in Q1 2026, an estimated $343K.
Michael Gelband first reported a position in Galectin Therapeutics in Q4 2018 and held it in 5 quarters.
Michael Gelband's Galectin Therapeutics position peaked at $362K in Q1 2019.
99 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.